You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability

Citation Tools

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS04. Endometrial/Uterine corpus cancers
PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Corr B, Thomas S, Haight P, et al
PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability
International Journal of Gynecologic Cancer 2023;33:A43-A44.